Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$7.14 USD
+0.23 (3.33%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $7.14 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.14 USD
+0.23 (3.33%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $7.14 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 29.41% and 169.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?
by Zacks Equity Research
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -12.90% and 9.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of -14.29% and 30.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -2.17% and 79.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
by Ekta Bagri
With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
Wall Street Analysts Predict an 110.53% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 110.5% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Tango Therapeutics, Inc. (TNGX)? Wall Street Analysts Think 115.31%
by Zacks Equity Research
The consensus price target hints at an 115.3% upside potential for Tango Therapeutics, Inc. (TNGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
IDEAYA Biosciences, Inc. (IDYA) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why
by Zacks Equity Research
The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.
What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 34.29% and 108.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Repligen (RGEN) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 8.16% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Acadia (ACAD) Soars 24.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 11.11% and 13.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Q1 Earnings Beat Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 8.51% and 0.09%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 8.33% and 2.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Mirati (MRTX): Can Its 13.5% Jump Turn into More Strength?
by Zacks Equity Research
Mirati (MRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of -3.13% and 15.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -2.38% and 28.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -1.20% and 64.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?